AtriCure price target raised to $50 from $40 at Piper Sandler

Piper Sandler analyst Matt O’Brien raised the firm’s price target on AtriCure (ATRC) to $50 from $40 and keeps an Overweight rating on the shares. The firm notes Atricure reported full Q4 results that represent a strong end to last year. Management already guided sales for 2025 and also provided some commentary on the call that might be a little disappointing, but Piper believes they are taking their typical conservative stance with their verbiage.